Damning new evidence has linked Covid mRNA shots to the recent surge in a new phenomenon doctors are calling “hyperprogressive cancers.”
The evidence shows the harmful effects on the human body caused by a unique, rare class of antibodies called IgG4.
IgG4 is caused by repeat injections of mRNA Covid vaccines.
These IgG4 antibodies are usually created in response to persistent irritants such as worms.
Unfortunately, repeat injections of mRNA Covid vaccine are perceived by our immune systems as a ‘persistent irritant’ and cause the IgG4 antibody switch.
The ‘persistent irritation’ effect possibly occurs not only because of repeat injections but also due to mRNA gene expression never stopping in half of the vaccinated people.
Are these IgG4 antibodies harmless? Do they have any effects outside of our immune reactions to COVID-19? Is there something to worry about?
Unfortunately, a 2020 study published in the British Medical Journal’s Journal for Immunotherapy of Cancer suggests that having more IgG4 antibodies — of any kind – enhances cancer progression.
The study authors found cancer-enhancing effects of any IgG4 antibodies in people and laboratory mice:
RESULTS: In a cohort of patients with esophageal cancer we found that IgG4-containing B lymphocytes and IgG4 concentration were significantly increased in cancer tissue and IgG4 concentrations increased in serum of patients with cancer.
Both were positively related to increased cancer malignancy and poor prognoses, that is, more IgG4 appeared to associate with more aggressive cancer growth.
We further found that IgG4, regardless of its antigen specificity, inhibited the classic immune reactions of antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity against cancer cells in vitro, and these effects were obtained through its Fc fragment reacting to the Fc fragments of cancer-specific IgG1 that has been bound to cancer antigens. …
We found that local application of IgG4 significantly accelerated growth of inoculated breast and colorectal cancers and carcinogen-induced skin papilloma.
We also tested the antibody drug for cancer immunotherapy nivolumab, which was IgG4 in nature with a stabilising S228P mutation, and found that it significantly promoted cancer growth in mice.
This may provide an explanation to the newly appeared hyperprogressive disease sometimes associated with cancer immunotherapy. (emphasis added, here and below)
The scientists provide an excellent explanation of the IgG4 antibody subclass:
IgG4 is a unique antibody that has the lowest concentration among IgG subtypes in healthy individuals, and its function has not been well understood. IgG4 was regarded as a ‘blocking antibody’ because of its reduced ability to trigger effector immune reactions.
Therefore whatever molecules IgG4 reacts to, the subsequent immune reaction was subdued.
The study details Wang et al.’s multidimensional investigation of IgG4 in a wide array of patients with cancer and tissues with both in vitro and in vivo experiments.
Again, this research was done in 2020, well before the effects of Covid vaccines on IgG4 could be seen.
After collecting blood and tissue samples from 82 patients, scientists found that greater levels of IgG4 were associated with higher grade (cancer grade is the tumor’s degree of malignancy) and poor prognosis.
Do IgG4 antibodies cause worse cancer outcomes, or do worse cancers create more IgG4? What is the horse and what is the cart here?
The rest of the scientific study tries to answer this question, and scientists conclude that IgG4 drives malignancy and aggressiveness of the real-life cancers they observed.
They found that even non-cancer-specific IgG4 inhibited immune reactions to cancer cells. Since human experiments of this kind would be unethical, authors instead experimented with mouse models.
The authors describe hyperprogressive disease that occurs due to certain monoclonal IgG4-based antibody nivolumab, despite previous hopes of its potential usefulness.
Recent awareness of hyperprogressive disease (HPD) associated with anti-PD-1 and anti-PD-L1 monoclonal antibody treatment for cancer has caught widespread attention, but no consensual explanation for this phenomenon has arrived.
HPD appeared to be a common complication for immunotherapy with nivolumab in many cancer types, including head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer and so on.
Our findings suggest that these IgG4 antibody drugs might have undesired side effects of inhibiting local immune responses and indirectly promote cancer growth.
When the specific target molecule is present in cancer, these IgG4 antibody drugs might be effective.
However, when the targets are absent or scanty, the IgG4’s immune inhibitory effect might prevail and accelerate cancer growth.
This possible detrimental effect of IgG4 might contribute to HPD in patients treated with PD-1 targeting drugs with IgG4 structure.
What is “hyperprogressive disease”? It is the same thing as “turbo-cancer,” of course, but it is a more fitting scientific term.
The authors conclude:
There appears to be a previously unrecognised immune evasion mechanism with IgG4 playing an essential role in cancer microenvironment with implications in cancer diagnosis and immunotherapy.
Cancer Deaths Increase in Australia
Unfortunately, relatively few recent cancer statistics are officially available.
An internet researcher named the Ethical Skeptic found some recent alarming numbers.
Data shows a 7% increase in cancer deaths reported in Australia, a highly vaccinated country.
Since cancers typically take years to develop and grow, such an increase is concerning, given that only two years passed since Australians received their “safe and effective” vaccines.
What the evidence shows is that some cancers, possibly treatable before mRNA injections, may become aggressive and difficult to treat.
The condition is what the BMJ study authors call “hyperprogressive disease.”